Optimal Clinical Trials Ltd | Auckland, New Zealand

Research site

(Unclaimed)

Location

Level 2,97 Grafton Road Grafton, Auckland, Auckland, New Zealand

Site insights

Top conditions

Top treatments

BI 456906

BTX 1204

ZGN-1061

KAN-101

Filgotinib

Molnupiravir

Bimagrumab

Ocrelizumab

Survodutide

Q-122

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

13 of 36 total trials

Locations recently updated

A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023) (MOVe-NOW)

Researchers are looking for other ways to prevent severe illness from COVID-19. COVID-19 is a virus that most often causes mild flu or cold-like symp...

Enrolling

Coronavirus Disease (COVID-19)

Drug: Placebo

Drug: Molnupiravir

A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis (Ocarina II)

This study will evaluate the pharmacokinetics, pharmacodynamics, safety, immunogenicity, and radiological and clinical effects of subcutaneous (SC) a...

Active, not recruiting

Primary Progressive Multiple Sclerosis

Relapsing Multiple Sclerosis

Drug: Ocrelizumab SC

Drug: Dexamethasone given orally

A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)

This study is to evaluate the Pharmacodynamic (PD), safety, tolerability, Pharmacokinetic (PK), and plasma biomarker response of KAN-101 in participa...

Active, not recruiting

Celiac Disease

Drug: Cohort 2 in Part A

Drug: Group 4 in Part B and Part C

A Study of TAVO101 in Atopic Dermatitis Patients

This is a Phase 2 pilot study to examine the preliminary efficacy, safety and PK of TAVO101 in adult patients with moderate and severe AD.

Active, not recruiting

Atopic Dermatitis

Drug: TAVO101

A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years

The purpose of this study is to demonstrate the efficacy of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) compared to placeb...

Active, not recruiting

Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention

Biological: ExPEC9V

Other: Placebo

A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age

The main purpose of Part A of this study is to evaluate the safety and tolerability of mRNA-1345 vaccine and to demonstrate the efficacy of a single...

Active, not recruiting

Respiratory Syncytial Virus

Drug: Placebo

Drug: mRNA-1345

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases

This study is the first-in-human (FIH) study of BGB-45035. The study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics o...

Enrolling

Atopic Dermatitis

Healthy Adult Participants

Drug: Placebo

Drug: BGB-45035

A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have ca...

Active, not recruiting

Obesity

Drug: Placebo

Drug: survodutide

Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis

This is a Phase 2a efficacy and safety study of EVO301 for the treatment of adults with atopic dermatitis.

Enrolling

Eczema Atopic Dermatitis

Atopic Dermatitis (AD)

Biological: Placebo

Biological: EVO301

Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)

A study of sevasemten (EDG-5506) in Becker muscular dystrophy (known as CANYON) and pivotal cohort (known as GRAND CANYON). The EDG-5506-201 CANYON s...

Active, not recruiting

Becker Muscular Dystrophy

Drug: Placebo

Drug: Sevasemten 10 mg

SAD/MAD Safety and PK Study of RBN-3143 in Healthy and Atopic Dermatitis Subjects

RBN-3143 Background: PARP proteins are members of a family of seventeen ADP-ribosyltransferase (ART) enzymes that regulate cellular processes includi...

Enrolling

Atopic Dermatitis

Drug: RBN-3143

Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese

A phase 2 study to assess the efficacy of bimagrumab alone or in addition to semaglutide to assess efficacy and safety in overweight or obese men and...

Active, not recruiting

Overweight or Obesity

Obese

Drug: Semaglutide

Biological: Bimagrumab

SBD121, a Synbiotic Medical Food for RA Management

The aim of this randomised, double-blind, placebo controlled clinical food trial is to determine if the medical food SBD121 Synbiotic (prebiotic and...

Enrolling

Rheumatoid Arthritis

Other: Placebo

Other: SBD121